Brief: Elevation Oncology Announces FDA Fast Track Designation Granted To Seribantumab For Tumor-Agnostic Treatment Of Solid Tumors Harboring NRG1 Gene Fusions
25/05/2022 12:32
May 25 (Reuters) - Elevation Oncology Inc ELEV.O :
* ELEVATION ONCOLOGY ANNOUNCES FDA FAST TRACK DESIGNATION
GRANTED
TO SERIBANTUMAB FOR THE TUMOR-AGNOSTIC TREATMENT OF SOLID TUMORS
HARBORING NRG1 GENE FUSIONS
Source text for Eikon: ID:nPn3GJMcna
Further company coverage: ELEV.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Elevation Oncology
See all newsBrief: Elevation Oncology Terminates License Agreement With CSPC Megalith Biopharmaceutical
U.S. RESEARCH ROUNDUP- Crane, Ryder System, Terex
Brief: Elevation Oncology Says Concentra To Buy Elevation Oncology For $0.36 Per Share Plus CVR
Elevation Oncology Inc expected to post a loss of 19 cents a share - Earnings Preview
Brief: Elevation Oncology Inc - To Prepay Term Loan Under Loan & Security Agreement Dated July 27, 2022 - SEC Filing